Risk of new or recurrent cancer during treatment with biologics in patients with immune-mediated inflammatory diseases and previous cancer: a meta-analysis.

Isufi D, Schwarz CW, Jensen MB, Seidelin J, Skov L, Loft N

Open source

DOI
10.1007/s10238-025-01738-4
Published
2025 Jun 25
Container
Clinical and experimental medicine
Publisher
Not recorded
Open access
yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1007/s10238-025-01738-4,
  title = {Risk of new or recurrent cancer during treatment with biologics in patients with immune-mediated inflammatory diseases and previous cancer: a meta-analysis.},
  author = {Isufi D and Schwarz CW and Jensen MB and Seidelin J and Skov L and Loft N},
  year = {2025},
  journal = {Clinical and experimental medicine},
  doi = {10.1007/s10238-025-01738-4},
  url = {https://doi.org/10.1007/s10238-025-01738-4}
}

RIS

TY  - JOUR
TI  - Risk of new or recurrent cancer during treatment with biologics in patients with immune-mediated inflammatory diseases and previous cancer: a meta-analysis.
AU  - Isufi D
AU  - Schwarz CW
AU  - Jensen MB
AU  - Seidelin J
AU  - Skov L
AU  - Loft N
PY  - 2025
JO  - Clinical and experimental medicine
DO  - 10.1007/s10238-025-01738-4
UR  - https://doi.org/10.1007/s10238-025-01738-4
ER  - 

APA

D, I., CW, S., MB, J., J, S., L, S., & N, L. (2025). Risk of new or recurrent cancer during treatment with biologics in patients with immune-mediated inflammatory diseases and previous cancer: a meta-analysis.. Clinical and experimental medicine. https://doi.org/10.1007/s10238-025-01738-4

Source records